Estrogen replacement therapy: effects on the endogenous androgen milieuJames A Simon
George Washington University School of Medicine, Washington, D C, USA
Fertil Steril 77:S77-82. 2002
..To review the impact of exogenous estrogen replacement therapy (ERT) on the production, binding, and metabolism of ovarian and adrenal androgens...
- Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
James A Simon
George Washington University, 1850 M Street NW, Suite 450, Washington DC 20036, USA
Womens Health (Lond Engl) 3:29-37. 2007
..This formulation provides patients with a cosmetic-like treatment option that is effective and safe, delivers stable systemic estradiol levels, and may promote overall treatment compliance...
- Skeletal consequences of hormone therapy discontinuance: a systematic review
James A Simon
Obstetrics and Gynecology, George Washington University, 1850 M Street, Ste 450, Washington, DC 20036, USA
Obstet Gynecol Surv 61:115-24. 2006
....
- Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy
James A Simon
Women s Health Research Center, Laurel, MD 20707, USA
Am J Obstet Gynecol 188:92-9. 2003
....
- Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder
James Simon
Women s Health Research Center J S, Laurel, Maryland 20707, USA
J Clin Endocrinol Metab 90:5226-33. 2005
..Hypoactive sexual desire disorder (HSDD) is one of the most common sexual problems reported by women, but few studies have been conducted to evaluate treatments for this condition...
Endometrial safety of ultra-low-dose estradiol vaginal tabletsJames Simon
Women s Health and Research Consultants, Washington, DC 20036, USA
Obstet Gynecol 116:876-83. 2010
..To evaluate the endometrial hyperplasia and carcinoma rate after 52-week treatment with ultra-low-dose 10-microgram 17β-estradiol vaginal tablets in postmenopausal women with vaginal atrophy...
- Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet
James Simon
Women s Health and Research Consultants, Washington, DC 20036, USA
Obstet Gynecol 112:1053-60. 2008
..To evaluate the efficacy of ultra-low-dose 10-microgram 17beta-estradiol (E2) vaginal tablets for treatment of vaginal atrophy...
- Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials
Jean P Rowan
Clinical Research Consultancy, Ann Arbor, Michigan, and Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA
Clin Ther 28:921-32. 2006
....
- Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms
James A Simon
George Washington University School of Medicine, Washington, DC 20036, USA
Menopause 13:222-31. 2006
..45 g of micellar nanoparticle estradiol emulsion containing 8.6 mg of estradiol was safe and effective in providing significant relief of vasomotor symptom frequency and severity in postmenopausal women...
- Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women
James A Simon
Obstetrics and Gynecology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 20036, USA
Fertil Steril 90:1132-8. 2008
..To evaluate the safety and efficacy of synthetic conjugated estrogens B (SCE-B; 0.3 mg/d) for 12 weeks in the treatment of vulvovaginal atrophy in symptomatic, postmenopausal women...
- Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial
James A Simon
Obstet Gynecol 101:1020; author reply 1020-1. 2003
- Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial
Glenn D Braunstein
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, 90048, USA
Arch Intern Med 165:1582-9. 2005
..Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women...
- A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms
Marc F Botteman
Abt Associates Inc, Bethesda, MD, USA; Pfizer Inc, New York, NY, USA
Menopause 11:343-55. 2004
..However, 1/5 NA/NE seemed to be more cost-effective than 0.625/2.5 CEE/MPA. These findings can be used to further refine the role of CCHT and to improve formulary decisions...
- Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial
James A Simon
George Washington University, Washington, DC, USA
Obstet Gynecol 109:588-96. 2007
..To investigate safety and efficacy and identify the lowest effective dose of a new transdermal estradiol (E2) gel for relief of menopausal symptoms in a population of postmenopausal women...
- Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study
James A Simon
George Washington University School of Medicine, Washington, DC, USA
Clin Ther 24:1871-86. 2002
..CONCLUSION: When once-weekly alendronate 70 mg was compared with once-daily alendronate 10 mg in this study, 70-mg once-weekly alendronate was the preferred dosing regimen...
- Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen
James A Simon
George Washington University, 1850 M Street, NW, Suite 450, Washington, DC 20036, USA
Expert Opin Investig Drugs 16:2005-20. 2007
....
- Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age
Rebecca J Ferrell
Center for Population and Health, Georgetown University, Washington, DC, USA
Menopause 14:29-37. 2007
..This study describes age-related changes in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a 5-year prospective study of reproductive aging...
- Treatment of osteoporosis: combination therapies
James A Simon
Department of Obstetrics and Gynecology, George Washington University, School of Medicine, Washington, D.C, USA
Int J Fertil Womens Med 48:127-31; discussion 137-8. 2003
..The potential synergistic effects of combination therapies are just beginning to be explored. Until more information is available, recommendations for use of combination therapies should be limited to specific clinical situations...
- A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users
James A Simon
Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC, USA
Menopause 10:37-44. 2003
....
- Counseling patients who elect to discontinue hormone therapy
James A Simon
Department of Obstetrics and Gynecology, George Washington University, School of Medicine, Washington, D.C, USA
Int J Fertil Womens Med 48:111-6; discussion 137-8. 2003
..Counseling patients on which treatment options: raloxifene, bisphosphonate, calcitonin, or PTH are most appropriate for their situation is important to long-term compliance and a satisfactory reduction in fracture risk...
- Prevention and management of osteoporosis
James A Simon
Department of OB/GYN, The George Washington University School of Medicine, Washington, DC, USA
Clin Cornerstone . 2003
....
- Does osteopenia warrant treatment?
James A Simon
George Washington University School of Medicine, Washington, DC 20036 5803, USA
Menopause 12:639-48. 2005
..Initiation of antiresorptive therapy known to provide rapid efficacy can be particularly important in achieving the treatment goal in appropriate osteopenic women...
